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Background: We aimed to evaluate and define the general clinical applicability and impact of pulmonary
radioaerosol mucociliary clearance (PRMC) on the work up of patients suspected of having primary ciliary dyskinesia
(PCD). In addition, we wanted to evaluate the accuracy of the reference values used in the PRMC test.
Methods: Measurement of PRMC after inhalation of 99mTc-albumin colloid aerosol was carried out on 239 patients
(4–75 years of age) during a 9-year period. All were referred to the nuclear medicine department because of clinical
suspicion of PCD. The results were compared primarily to results from nasal ciliary function testing, to electron
microscopic (EM) examination of the ultrastructure of the cilia, and to the final clinical diagnosis.
Results: Of the 239 patients, 27 ended up with a final clinical diagnosis of definitive PCD. No patients with a PRMC
test that was normal or otherwise not consistent with PCD ended up with PCD as final clinical diagnosis (though a
minority of patients in this group ended up unresolved in regard to PCD). Forty percent of patients with an
abnormal PRMC test ended up with PCD as final clinical diagnosis. Furthermore, the PRMC test had a high rate of
conclusive results (90 %). Children <14 years of age with normal PRMC measurements showed significantly faster
lung clearance than adults with similarly normal PRMC measurements.
Conclusions: To this date, PRMC is the only test providing evaluation of the mucociliary clearance of the entire
lung. Its greatest strength is its ability to reject a suspected PCD diagnosis with great certainty. In our material, this
accounted for 2/3 of referred patients. In addition, the test has a high rate of conclusive results. According to our
analyses, reference equations on children would benefit from updated data.
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Mucociliary clearance is known to be an important in-
nate defence mechanism against inhaled microbes and
irritants. Potentially harmful substances get trapped in
the mucus layer lining the airways, and subsequently,
the synchronised movement of the cilia propels the
mucus to the pharynx where it will be swallowed. This
mechanism can be hampered either by conditions affect-
ing the constitution of the mucus (such as cystic fibrosis,
chronic obstructive pulmonary disease, or asthma) or by* Correspondence: jann.mortensen@regionh.dk
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medium, provided the original work is properlyconditions directly affecting the movement of the cilia.
This last group of conditions has traditionally been di-
vided into primary and secondary ciliary dyskinesia
(PCD and SCD). PCD is a genetic disorder caused by mu-
tations in genes in relation to the axoneme. Clinically, the
patients present with cough, dyspnea, and recurrent air-
way infections starting from early childhood. However, it
is both genetically and phenotypically a heterogeneous
condition presumably reflecting the molecular complexity
of the axoneme, and for this same reason, diagnosing
these patients can be challenging. SCD on the other hand
includes a variety of temporary, acquired defects of ciliary
movement caused by viral or bacterial infection or by cer-
tain air pollutants. In some instances, it can be difficult tos article distributed under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited.
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ings in the tests meant for diagnosing PCD [1].
Although there is no definitive evidence that early
diagnosis of PCD is beneficial, there is emphasis on find-
ing and treating these patients as early as possible, since
early and aggressive treatment of lung infections is
thought to be crucial in the prevention of future lung
damage [2–4].
The diagnosis relies on the clinical assessment of the
patients combined with an array of different tests. These
typically include measurement of nasal nitric oxide
(nasal NO) where a low NO-value points towards PCD
and vice versa, electron microscopic (EM) examination
of the ultrastructure of the cilia, and microscopy of
ciliary beat pattern and frequency. Genetic testing is
developing rapidly, but to this date, only some of the
disease-causing genes are known and currently around
65 % of patients could be detected this way [5–7].
Highly specialised modalities used in only few centres
are (1) culture of respiratory cells at an air-liquid
interface with reanalysis of the ultrastructure of cilia
and microscopy of ciliary beat pattern and frequency,
(2) immunofluorescence microscopy of respiratory
cells, which allows visualisation and localisation or
demonstration of the absence of specific proteins in
relation to the cilia, and (3) EM tomography, which
due to its high resolution may be able to identify ul-
trastructural defects where normal EM has not deter-
mined the abnormality [7–10].
While EM of the cilia and ciliary function testing are
both time consuming and somewhat invasive, nasal NO
measurement is a fast, non-invasive tool that can gener-
ally be used from 5 years of age (modified techniques
have been shown to be applicable from 2.5 years) [2, 11]
when it comes to targeted case finding and excluding of
PCD. But still, there is a need for further investigation
when nasal NO values are either inconclusive or point
towards PCD [2]. At our centre, measurement of pul-
monary radioaerosol mucociliary clearance (PRMC) has
been used as part of diagnostic routine tools in the work
up of patients suspected of having PCD for over a dec-
ade. This method draws on the fact that patients with
PCD have impaired mucociliary clearance as a result of
abnormal ciliary motility [12]. This abnormal clearance
pattern can be visualised for the entire lung using a gamma
camera to follow the movement of an inhaled radioaerosol.
PRMC is non-invasive, renders a minimal amount of radi-
ation (less than 1 mSv while the yearly background radi-
ation in Denmark is 3–4 mSv), is applicable to children as
young as 5 years of age (younger children will normally ex-
hibit a lack of cooperation), and most importantly a normal
PRMC can help excluding the diagnosis in patients with
symptoms compatible with PCD who might exhibit SCD in
the nasal biopsy [13, 14]. In addition, the PRMC test isrelatively easy to perform. A simplified protocol for
the test is presented in our review published in 2013
[1]. A large number of patients referred for PRMC as
work up of PCD diagnosis are children. However, our
current reference equations are generated on a group of
healthy people >17 years of age. It is still unknown if
extrapolating the equations to this younger age group will
bias interpretation of results.
The aim of this study is to evaluate and define the
general clinical applicability and impact of PRMC on the
work up of patients suspected of having PCD. Moreover,
the reference values used today will be scrutinised—e-




The study was carried out as a register-based follow-up
study. The patients were included continuously over
9 years, and their final clinical diagnosis was evaluated at
the end of the study period.
Patients
In total, 239 patients were included in the study, and all
were referred to the nuclear medicine department for
PRMC test because of clinical suspicion of PCD. The
vast majority of these had PRMC done as part of their
work up for PCD in the National PCD Centre in
Copenhagen at Rigshospitalet, whereas 64 patients were
referred directly from departments of pulmonary medi-
cine in other hospitals, and they were only referred to
the National PCD Centre in Copenhagen if the clinical
suspicion of PCD sustained after completion of the
PRMC test.
Preceding the PRMC test, patients were informed
that they had to be without symptoms of acute airway
infections 4–6 weeks prior to the test. Some patients
had their PRMC test repeated during the study
period; but in this paper, when nothing else is stated,
only results from the first PRMC test are used.
PRMC test
The PRMC technique has been described in detail earl-
ier [15]. In brief, the patients inhaled an ultrasonically
nebulised 99mTc-albumin colloid with a mass median
aerodynamic particle diameter of 3.4 μm. They did 20
tidal breathings with slow inspiration followed without
breath hold by forced expiration, and the radioaerosol
was administered during the whole inspiration phase.
Inhalation volume was not measured. Immediately
after the inhalation procedure, the patients rinsed
their mouth by gargling three times. Thereafter, lung
radioactivity was detected by placing the patients in a
supine position against a posteriorly positioned gamma
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counts per second was obtained. If not, extra inspirations
were made.
Measurement of lung radioactivity was performed for
the next 2 h with static acquisitions at 0, 60, and
120 min together with two 20-min dynamic acquisitions
(films) in the first hour. This was supplemented with a
15-min static acquisition after 24 h.
Regional ventilation distribution was assessed by
an 81mKr-gas scintigram. The initial 99mTc aerosol
distribution was compared to this 81mKr ventilation
distribution by calculating a penetration index (PI),
which reflects how far the radioaerosol had pene-
trated into the lungs, thereby indicating how far the
radioaerosol had to move before being cleared from
the airways. Using our reference equations which are
based on a cross-sectional study of 53 healthy never-
smoking adults (18 to 84 years) [16], the PI, sex, and age of
the subject was used to calculate his or her predicted lung
retention at 1 and 2 h (pLR1 and pLR2). These predicted
values were then compared to the actual measuredFig. 1 Twenty-minute dynamic posterior acquisition presented as eight pic
transport. Boluses of mucus are seen to ascend from the main stem bronc
four pictures). In the midline, two 57Co markers placed above the vertebra Clung retention at 1 and 2 h (LR1 and LR2) corrected
for background and physical decay.
The difference between predicted and actual lung
retention divided by the standard deviation was cal-
culated as a Z-score for LR1 and LR2, respectively.
The upper limit for a normal test was defined as a
Z-score of >1.645 (i.e., 95 percentile), since an ab-
normal mucociliary clearance can only be too slow,
resulting in too high retention.
The two 20-min dynamic acquisitions were used to as-
sess mucus transport in the larger airways. When bolus
transport occurred, distinctive radioactive boluses could
be seen to move through the main stem bronchi and the
trachea (Fig. 1). The movement was visually assessed as
normal, abnormal (i.e., slow, absent, or retrograde), or
inconclusive.
The interpretation of the PRMC test was based on the
following three questions: (1) Were LR1 and LR2 outside
the predicted values? (2) Was the bolus transport in the
trachea abnormal? And (3) was focal retention seen in
the airways after 24 h? A “yes” to all questions indicatedtures each representing 2½min of normal tracheobronchial bolus
hi to the trachea (top four pictures) and further up the trachea (bottom
7 and L1 are seen over the trachea and under the lungs, respectively
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clearance. A regional impaired clearance was the case, if
there were one or a few focal retentions at 24 h, while
the other two parameters were normal. In other cases of
inconsistencies, the test was read as inconclusive (see
below).
Generally, the interpretation of the PRMC tests can be
divided into three main groupings: (1) where the test is
clearly abnormal rendering PCD or SCD possible expla-
nations, (2) where the test is inconclusive whereby PCD
cannot be ruled out, or (3) where the test is normal or
otherwise not consistent with PCD. If for example one
or a few focal retentions were seen at 24 h, this would
imply overall normal clearance with only regional im-





Fig. 2 Three examples of posterior static acquisitions from a normal, an ab
deposition together with remaining aerosol deposition after 2 and 24 h. Tw
position the patient. Top row: normal PRMC test. LR2 was 38 % (predicted =
PRMC test. The radioaerosol is seen to be initially centrally deposited, and a
24 h. LR2 was 100 % (predicted = 72 %, upper normal limit = 88 %, Z-score
(predicted = 77 %, Upper normal limit = 93 %, Z-score = 0.8), but a distinct f(3). As another example, some patients show signs of
SCD but not PCD (e.g., slow clearance indicated by ab-
normal LR1 and/or LR2 but normal retention at 24 h
and normal bolus transport in central airways), and such
a test would as well be placed in group (3). This means
that PRMC has the ability to discern between PCD and
SCD in some but not all cases. Examples of static acqui-
sitions from an abnormal, a normal, and a regional ab-
normal test, respectively, are seen in Fig. 2.
An inconclusive test is usually a result of one of the
following causes: (1) cough during examination, (2) in-
consistency between LR1 and LR2 values, bolus trans-
port, and 24-h retention, or (3) very peripheral
radioaerosol deposition, which can cause the predicted
normal range for lung retention (pLR1 or pLR2 + 1.6452 hours 24 hours
normal, and a regional abnormal PRMC test showing initial aerosol
o 57Co markers over the cervical and lumbar spine are used to help
70 %, upper normal limit = 86 %, Z-score = -3.3). Centre row: abnormal
fter 2 h, very little is cleared. The same foci are still very distinct after
= 2.9). Bottom row: regional abnormal PRMC test. LR2 was 85 %
ocus is seen in the left lung after both 2 and 24 h
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problem is minimised by means of the inhalation technique
described earlier, which serves to promote deposition of the
radioaerosol in the central airways.
As noted, if the patient coughs during the first 2 h of the
PRMC test, an apparently normal test will be interpreted as
inconclusive. This is due to the fact that the clearance
measured may be the result of cough clearance in-
stead of clearance due to ciliary movement. Hence,
an effective cough clearance would be able to dis-
guise a true abnormal clearance leading the test to
appear as being normal (i.e., false negative). In con-
trast, an abnormal test is still considered reliable
despite coughing (i.e., true positive). Consequently, a
staff member monitored the patients during the first
2 h of the test and registered time and number of
coughs and throat clearing. Subsequently, all patients
who had coughed in this timeframe had to perform
a 1-min voluntary cough clearance test immediately
after the 2-h acquisition, which served as a measure
for the effectiveness of their coughing with regard to
airway clearing. If this test showed minimal cough
clearance, an otherwise normal PRMC test could be
regarded as being normal provided that the cough
during the first 2 h of the test had been very limited
(say 1–2 small coughs or huffs). The voluntary
cough clearance test is not thought to affect the in-
terpretation of the 24-h scan, since this scan is pre-
dominantly determined by retention in the smaller
bronchi, bronchioles, and possibly bronchiectasis
which is only marginally affected by cough clearance,
since coughing is thought mainly to affect the first
six airway generations [17]. In addition, no restric-
tions are given to the patients with regard to cough-
ing in the timeframe before the 24-h scan.
Final clinical diagnosis
The final clinical diagnoses were primarily obtained via
national electronic hospital records, in which we were
able to search for each patient by means of their unique
social security number. In a few cases, this information
was complemented with non-electronic records from
the National PCD Centre in Copenhagen. Results from
EM and ciliary function testing were found in a database
in the National PCD Centre in Copenhagen where these
tests are being performed. A description of these two
methods can be found in the ERS recommendations for
PCD [18]. All patients in Denmark with a verified, de-
finitive PCD diagnosis are followed on a regular basis in
the National PCD Centre in Copenhagen. Therefore,
these patients were easy to identify.
Optimally, all patients in the study should have had
their tentative PCD diagnosis confirmed or refuted after
the completion of both thorough clinical assessment,nasal NO measurement, EM, ciliary function testing,
PRMC, and in some cases gene testing. Because of the
set-up of the study, the different tests were done only
when considered pertinent by the treating doctor, mean-
ing that only some of the patients were examined this
comprehensively.
For a minority of the patients (32 out of 239), a con-
clusion could not be reached with regard to their final
clinical diagnosis. This was most often due to lack of in-
formation in the national electronic hospital records or
due to on-going work up of a patient with contradicting
test results.
Statistical analysis
Two-sample t test for means was used for comparisons
unless both groups were larger than 30, in which cases a
z test was performed instead. Comparisons were done
between PI in patients with a normal and abnormal
PRMC test and between PI and Z-scores for LR1 and
LR2 for children vs. adults with a normal PRMC.
Ethics




In total, 239 patients with an age range of 4 to
75 years were included in this study (Table 1).
23.8 % had a positive PRMC test (PCD/SCD), 10.5 %
had an inconclusive test while the remaining 65.7 %
had a test that ruled out PCD. The PRMC results
were rather uniformly distributed with regard to age
with only the group of 55- to 75-year-old patients
having a lower percentage of abnormal (7.1 %) and
inconclusive results (3.6 %) than the other groups
(abnormal ~20–35 % and inconclusive ~6–13 %).
Consequently, they also had a higher percentage of
results that were normal or otherwise not consistent
with PCD.
PRMC results in relation to final clinical diagnosis
No patient with a PRMC test that ruled out PCD ended
up with PCD as final clinical diagnosis (Table 2)—that
is, there were no false negatives. However, 29 % of pa-
tients in this group ended up with an uncertain final
clinical diagnosis.
The final clinical diagnoses of patients with an abnor-
mal PRMC test were somewhat more variable. 40 %
ended up with verified PCD while 39 % had the PCD
diagnosis rejected—that is, 39 % of the positive PRMC
tests were false positives. At the end of the study, 21 %
had an uncertain diagnosis. A similar variability in the
final diagnoses was seen amongst patients with an
Table 1 Distribution of PRMC results in relation to age
Results from PRMC test Age group
4–14 years 15–24 years 25–34 years 35–54 years 55–75 years All
n = 105 (%) n = 28 (%) n = 34 (%) n = 44 (%) n = 28 (%) n = 239 (%)
PCD/SCD 21 (20) 9 (32.1) 12 (35.3) 13 (29.5) 2 (7.1) 57 (23.8)
[14, 67 %] [3, 33 %] [3, 25 %] [3, 23 %] [0] [23, 40 %]
Inconclusive 14 (13.3) 3 (10.7) 2 (5.9) 5 (11.4) 1 (3.6) 25 (10.5)
[4, 29 %] [0] [0] [0] [0] [4, 16 %]
Normal or otherwise not consistent with PCD 70 (66.7) 16 (57.1) 20 (58.8) 26 (59.1) 25 (89.3) 157 (65.7)
[0] [0] [0] [0] [0] [0]
Numbers in square brackets show the number and percentage of patients in each group ending up with verified PCD as final clinical diagnosis
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cases while it was verified in 16 %. At the end of the
study, 20 % had an uncertain diagnosis.
The highest percentage of patients ending up with
verified PCD as final clinical diagnosis were seen
amongst children 4–14 years old (67 % of patients hav-
ing an abnormal PRMC test) while no patients ≥55 years
ended up with the final clinical diagnosis of PCD
(Table 1). All four patients with an inconclusive PRMC
test that ended up with PCD as final clinical diagnosis
were ≤14 years. The reason for their PRMC tests being
inconclusive was pronounced coughing resulting in LR1
and LR2 values within the normal range while bolus
transport and 24-h static acquisition were abnormal.
PRMC results in relation to ciliary function testing, EM,
and final clinical diagnosis
As mentioned earlier, not all patients underwent the full
work up for PCD whereby it has only been possible to
compare PRMC results with ciliary function testing and
EM in 108 and 79 cases, respectively (Tables 3 and 4).
Seventy-two patients had both tests performed. As a
whole, there was good concordance between the three
different test results and the final clinical diagnoses.
However, in some cases, significant discrepancies were
seen between results. This was mainly (1) patients with a
PRMC test ruling out PCD but with an abnormal EM or
ciliary function test who ended up with a final clinical
diagnosis rejecting PCD, (2) patients with an inconclu-
sive PRMC test, an abnormal EM or ciliary function test,Table 2 PRMC results in relation to final clinical diagnosis
Final clinical diagnosis
Results from PRMC test Verified PCD Uncertain but probably PCD U
n = 27 (%) n = 3 (%) n
PCD/SCD 23 (85.2) 2 (66.6) 7
Inconclusive 4 (14.8) 1 (33.3) 3
Normal or otherwise not
consistent with PCD
0 (0) 0 (0) 2and a final clinical diagnosis rejecting PCD, (3) patients
with an abnormal PRMC test but a normal EM who
ended up with a final clinical diagnosis confirming PCD,
or (4) patients with an abnormal PRMC test and abnor-
mal EM or ciliary function test but with a final clinical
diagnosis rejecting PCD. All cases with discrepant re-
sults have been marked with asterisk in Tables 3 and 4,
and moreover, further information about each of these
patients is presented in Table 5 (please note that some
of the 23 marked patients in Tables 3 and 4 are the same
so that they represent only 21 different patients).
Inconclusive tests
In our study, 90 % of patients had a conclusive result
after just one PRMC test.
Unfortunately, only 10 out of 25 patients with an ini-
tially inconclusive PRMC test had a new PRMC test per-
formed. However, 8 out of these 10 patients obtained a
conclusive test after repeating the PRMC test once. Two
patients needed more than one repetition.
Comparison of penetration index and retention in
different groups
When comparing mean PI from patients with a normal
and abnormal PRMC test, respectively, we found no sig-
nificant difference between the two groups suggesting that
a more peripheral initial deposition was not the cause of
the observed abnormal clearance (mean PI for normal
PRMC= 0.478, mean PI for abnormal PRMC= 0.524, CI
for difference in means = (-0.0189; 0.111)).ncertain Uncertain but probably not PCD Not PCD Total
= 32 (%) n = 28 (%) n = 149 (%) n = 239 (%)
(21.9) 3 (10.7) 22 (14.8) 57 (23.8)
(9.4) 1 (3.6) 16 (10.7) 25 (10.5)
2 (68.7) 24 (85.7) 111 (74.5) 157 (65.7)
Table 3 PRMC results in relation to ciliary function testing and final clinical diagnosis
Results from ciliary motility study Final clinical diagnosis related to results from PRMC and ciliary motility study













n = 45 (%) n = 17 (%) n = 46 (%) n = 25 (%) n = 2 (%) n = 7 (%) n = 3 (%) n = 71 (%)
PCD/SCD 26 (57.8) 22 (88) 1 (50) – – 3a (4.2)
2 (11.8) – – – – 2 (2.8)
15 (32.6) – – 3 (42.8) 1 (33.3) 11 (15.5)
Inconclusive 8 (17.8) 3 (12) – 1 (14.3) – 4a (5.6)
2 (11.8) – 1 (50) – – 1 (1.4)
8 (17.4) – – 1 (14.3) – 7 (9.9)
Normal or otherwise not
consistent with PCD
11 (24.4) – – 1 (14.3) – 10a (14.1)
13 (76.4) – – 1 (14.3) 2 (66.6) 10 (14.1)
23 (50) – – – – 23 (32.4)
aCases with discrepant results. Further information about each of these patients is presented in Table 5
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was compared amongst patients who had a perfectly
normal PRMC test (Fig. 3a–c). When comparing
children (5–14 years) with adults (>14 years), signifi-
cant differences were found in the case of retention
Z-scores for LR1, retention Z-scores for LR2, and PI
(Table 6).
Discussion
With its 239 patients, this is by far the largest study to
date concerning clinical use of the PRMC test. Further-
more, it is the first study presenting a large data set from
PRMC tests used as part of everyday clinical work up of
patients suspected of having PCD.
According to our study, the main strength of the
PRMC test is its ability to rule out an otherwise sus-
pected PCD diagnosis since the study showed that no
patient with a normal PRMC test or a PRMC testTable 4 PRMC results in relation to EM and final clinical diagnosis










n = 23 (%) n = 13 (%) n = 44 (%) n =
PCD/SCD 18 (78.3) 17 (
5 (38.5) 2 (7
16 (36.4) 3a (1
Inconclusive 3 (13.0) 2 (7
3 (23.0) 1 (3







aCases with discrepant results. Further information about each of these patients is potherwise not consistent with PCD ended up having
PCD as final clinical diagnosis—that is, we experienced
no false negatives. Only 10 % of tests were inconclusive,
and of these, only 16 % had a final clinical diagnosis of
PCD. The fact that no patients >14 years with an incon-
clusive test result ended up with a definite PCD diagno-
sis means that even an inconclusive test in adults
strongly suggests that PCD is very unlikely.
To this date, there are only few studies on the usage of
PRMC in relation to PCD. Most of these studies deal
only with a very limited number of patients and espe-
cially the number of PCD patients in each study is
sparse [19–22]. However, these studies do show mark-
edly reduced tracheobronchial clearance in patients
with known PCD compared with healthy individuals
which is in alignment with our results. Most recently,
this was found by Walker et al. in a comparison of six PCD
patients and four healthy controls [23]. In our earlier largel clinical diagnosis related to results from PRMC and EM study






26 (%) n = 2 (%) n = 4 (%) n = 2 (%) n = 46 (%)
65.4) – – – 1 (2.2)
.7) – 1 (25) – 2 (4.3)
1.5) 1 (50) 1 (25) – 11 (23.9)
.7) – – – 1a (2.2)
.8) – – – 2 (4.3)
.8) 1 (50) 1 (25) 1 (50) 3 (6.5)
– 1 (25) – 1a (2.2)
– – 1 (50) 4 (8.7)
– – – 21 (45.7)
resented in Table 5
Table 5 Elaboration of patients with significant discrepancies between test results
Variables Patient
1 2 3 4 5
Age, years 15 6 15 17 10
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Final clinical
diagnosis
Not PCD Not PCD Not PCD Not PCD Not PCD
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these patients had known PCD or were diagnosed during
the course of the study. The study was divided into three
sequentially performed substudies: (1) a cross-sectional
study of patients with known PCD which showed abnormal
PRMC in 14 out of 15 patients (one PRMC was inconclu-
sive), (2) a prospective blinded trial in which PRMC was
tested against EM and ciliary function testing which
showed good concordance between the different methods,
and (3) an implementation study using PRMC as part of
the routine work up of 21 patients referred for PCD investi-
gation. It was concluded that in a selected group of pa-
tients, PRMC would be a good supplementary test in the
diagnosis and exclusion of PCD. These observations were
generally corroborated by our present results, which were
obtained from a very large group of patients in which the
PCD diagnosis was not established beforehand. Even
though the described implementation study with 21 pa-
tients should assess PRMC as a routine method in PCD
work up, one might think that the selection of patients for
the trial have been affected by the fact that this new method
was suddenly available to a large group of patient suspected
of having PCD. One might speculate that patients with the
highest suspicion of PCD would then be referred to the
PRMC test first. This is in line with the fact that 6 out of 21(29 %) had PCD as final clinical diagnosis compared with
11 % in the present study. Therefore, we think that our
present study better represents what to expect from the
PRMC test if implemented in the everyday work up of sus-
pected PCD patients. In addition, because of the large
number of patients included in this study, for the
first time, we have been able to analyse data from 42
children presenting perfectly normal PRMC tests in
order to assess the reference material used today.
PRMC results in relation to final clinical diagnosis
As mentioned, one of the biggest strengths of the PRMC
test is its ability to rule out PCD. This is supported by
the fact that we found no false negatives in the present
study.
In addition, in a selected group of patients apparently
the test has the ability to point out patients that are
likely to have PCD. In our study population, when the
PRMC test was abnormal, 40 % ended up having PCD as
final clinical diagnosis. This means that an abnormal test
to some degree supports the PCD diagnosis, though it is
important to remember that the ability to diagnose PCD
is not the main advantage of the test.
Another reason, why the PRMC test is a useful clinical























































Fig. 3 a Retention Z-score for LR1 in relation to age in patients with a perfectly normal PRMC test (this is defined as a normal PRMC test showing
no signs of regional impaired clearance or slow clearance in any part of the lung in combination with no coughing or throat clearing during the
2-h PRMC test). Lower retention Z-scores represent better clearance. b Retention Z-score for LR2 in relation to age in patients with a perfectly
normal PRMC test. Lower retention Z-scores represent better clearance. c PI in relation to age in patients with a perfectly normal PRMC test.
Higher PI represents more peripheral initial deposition of the radioaerosol
Munkholm et al. EJNMMI Research  (2015) 5:39 Page 10 of 14one test, 90 % of patients had a conclusive result
(Table 1). Eighty percent of patients initially having an
inconclusive result obtained a conclusive test after only
one repetition. If looking at the subgroups of patients on
which either ciliary function testing or EM was per-
formed, the rates of conclusive results after the first testwere as follows: 69 % of ciliary function tests were con-
clusive compared with 83 % of PRMC tests. Seventy-five
percent of EM tests were conclusive compared with
84 % of PRMC tests.
As seen in Table 1, by far the largest number of pa-
tients having PCD as final clinical diagnosis was found
Table 6 Comparison of retention Z-scores and PI between






means (95 % CI)
p value
n = 42 n = 44
Z-score for LR1 −1.4 0.089 1.47 (1.05; 1.89) p < 0.001
Z-score for LR2 −1.7 −0.0023 1.65 (1.15; 2.15) p < 0.001
PI 0.40 0.61 0.2 (0.127; 0.276) p < 0.001
All the included patients had a perfectly normal PRMC test. (This is defined as
a normal PRMC test showing no signs of regional impaired clearance or slow
clearance in any part of the lung in combination with no coughing or throat
clearing during the 2-h PRMC test)
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an abnormal PRMC test while none over the age of 55
was diagnosed with PCD. This is in line with the clinical
presentation of the disease starting in early childhood
and most often resulting in severe airway symptoms
often leading to early work up.
Generally, the results from ciliary function testing and
EM were in good concordance with results from the
PRMC tests and the final clinical diagnoses. However,
some discrepancies were seen. Each of these cases has
been elaborated further, and they are all presented in
Table 5. In 17 out of the 21 cases (patient No. 1–17), the
observed discrepancy is thought to be due to SCD causing
false positive tests. In 10 out of these 17 cases (patient No.
8–17), the patient had a PRMC test not consistent with
PCD while the ciliary function testing was abnormal. The
fact that SCD could affect the results of ciliary function
testing and not PRMC could be explained in two ways:
First, the different tests are not necessarily performed at the
same point in time, which means that the degree of SCD af-
fecting the patient might differ between the two tests. Sec-
ond, and more importantly, one of the great advantages of
the PRMC test is that it is not affected by nasal SCD be-
cause the PRMC test examines the ciliary function of the
entire lung and not just the nasal ciliary function.
In four other cases (patient No. 18–21), a normal EM
was found while the rest of the tests were abnormal to-
gether with a final clinical diagnosis confirming PCD. This
is in line with a growing number of publications showing
normal EM tests in PCD patients [2, 9, 24, 25, 26].
Penetration index and Z-scores
We found no significant difference between the initial
aerosol distribution in the lungs (indicated by the mean
PI) in patients with a normal and abnormal PRMC test.
The magnitude of PI is accounted for when calculating
predicted values for LR1 and LR2. But if PI had been sig-
nificantly higher in patients with an abnormal PRMC
test, this would have implied that we did not to a satis-
factory degree take into account the magnitude of PI
when calculating predicted values. Fortunately this doesnot seem to be the case, which means that abnormal test
results are most likely caused solely by slow clearance of
the radioaerosol.
When comparing children and adults presenting per-
fectly normal PRMC tests, our results show markedly
faster clearance (i.e., lower Z-scores for LR1 and LR2) in
children than in adults. This might be an expression of
the fact that children under 14 years of age have smaller
lungs and thereby generally shorter airways than adults
[27]. Assuming that the cilia in healthy children and
adults work equally effective, it makes sense that shorter
airways means faster overall lung clearance.
It is also noteworthy that the mean PI in these children is
significantly lower (i.e., more central initial lung deposition)
than the mean PI seen in the corresponding adults. Ac-
cording to the discussion above, this should not affect the
results of the test seeing that the magnitude of PI is
accounted for in the calculation of predicted LR1 and LR2.
Nevertheless, it raises the question if the formulas for calcu-
lating predicted LR1 and LR2 to a satisfactory degree take
the magnitude of PI into account when used on children
under 14 years of age. If not, at least to some degree,
the low PI seen amongst the children might explain
the faster clearance observed. If the fast clearance
observed in children is primarily due to smaller lungs, it
would make sense to incorporate, e.g., the height of the
patient when calculating PI. As of today, PI only takes into
account the proportion of the lung receiving a certain de-
gree of radioaerosol. Thereby, the actual size of the lungs
and thus the length of the airways are not accounted for.
Whatever the explanation, according to our results, it
seems fair to state that the reference material used for
the PRMC test today does not in a satisfactory degree
take into account the effect of age (or height) on lung
clearance, which is most evident for children under
14 years of age. This is not surprising since our refer-
ence material is based upon a cross-sectional study of
53 healthy never-smoking adults (18 to 84 years)
meaning that predictive norms have been extrapolated
for ages <18. In the reference material, the dependency of
age on PRMC was weak [16]. But according to the present
study, this could be different if one incorporates chil-
dren <14 years in such a reference material. To date, no
reference material on PRMC in children exists.
Algorithm for work up of PCD in specialised centres with
access to PRMC testing
Based on our experience with work up of patients
suspected of having PCD, we propose the following
algorithm for PCD investigation (Fig. 4).
When patients have been referred to a specialist centre
with expertise in PCD work up, the ensuing work up
should take into account the strength of suspicion of
PCD based on history and clinical presentation of the
Fig. 4 Suggested algorithm for the work up of patients suspected of having PCD. The algorithm presupposes work up in a specialised centre
with access to PRMC testing. In our patient population, the PRMC test would obviate the need for further work up in relation to PCD in 2/3 of
the patients
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high or non-high, measurement of nasal NO levels
should be used as a first wave work up tool. The test is
easy to perform and non-invasive and is suitable as a tar-
geted case finding tool for PCD [2]. In patients with a
normal or high level of nasal NO together with a non-
high suspicion of PCD, the diagnosis could be ruled out.
If however the suspicion is high, further work up for
PCD should be performed since a few studies have
shown normal or elevated levels of nasal NO in patients
with known PCD [11, 13, 29]. A low level of nasal NO
points towards PCD, but other conditions such as cystic
fibrosis [30], panbronchiolitis [31], nasal polyposis [32],
and chronic sinusitis [32] have also been shown todemonstrate reduced levels of nasal NO. Therefore, a
measurement of low nasal NO should always be
followed by further work up to confirm or reject the
diagnosis. This work up should amongst other things
include a new nasal NO measurement after, e.g., 2–
3 months—preferably in a steady state with no or few
symptoms apart from those to be expected from the dis-
ease. If rising or normal values can then be attained, the
diagnosis might be rejected [33, 34].
Patients with initially high suspicion of PCD and all
patients with abnormal or inconclusive nasal NO values
should have PRMC performed. If the PRMC test is nor-
mal, PCD can be ruled out in accordance with the fact
that we found no false negatives in the present study. In
Munkholm et al. EJNMMI Research  (2015) 5:39 Page 13 of 14our setting, PCD could be ruled out in roughly two out
of three patients. An inconclusive test would require a
re-test (in the present study 80 % acquired a conclusive
result after only one re-test) while an abnormal test
should lead to more intensive work up with EM, ciliary
function testing, and possibly gene testing.
Strengths and weaknesses of the study
One of the main strengths of the present study is that it
shows what to expect of the PRMC test if implemented
in the everyday clinical work up of PCD. Another
strength is the large number of patients that are in-
cluded. By far, it is the largest study to date concerning
clinical use of the PRMC test. Furthermore, even when
taking into account the weaknesses mentioned in the
following, the fact that no patient with a normal PRMC
test ended up with PCD as final clinical diagnosis is
quite convincing. It is also worth noticing the very high
rate of conclusive results achieved with the PRMC test.
The main weakness of this study is that all of the
PRMC results have been used in the subsequent
work up of the patients, which means that these re-
sults have inevitably affected the final clinical diagnoses.
In addition, not all patients underwent the same thorough
work up for PCD. This was due to the fact that in some
patients, the assumed PCD diagnosis was easily rejected
leaving some tests unnecessary in the everyday clinical
work up for PCD. It would of cause be advantageous to
make a similar study with blinded results and with strict
protocols for the work up of all patients suspected of hav-
ing PCD. On a smaller scale, this was done by Marthin
et al. [14] in our substudy 2, which included 59 patients,
and as mentioned, those results are generally in line with
the results presented in the present work. Another weak-
ness of the present study is the lack of systematically col-
lected clinical information concerning smoking habits,
airway symptoms, and pulmonary diseases that might in-
fluence mucociliary clearance. On the other hand, we
know that all patients in general had unexplained airway
symptoms (or else they would not have been referred to
the PRMC test) and that they as far as possible had been
without acute airway infection 4–6 weeks prior to the test
as already explained.
Conclusions
In this study, we have evaluated the use of the PRMC
test in the work up of patients suspected of having
PCD. To this date, it is the only method for testing
the mucociliary function of the lower airways, and when
compared to other existing tests, one of its great strengths
is that it is not affected by secondary mucociliary defects
affecting nasal cilia. In addition, the test is non-invasive
and is applicable to children as young as 5 years of age.
The method is relatively easy to introduce and performand could therefore potentially be of interest for general
nuclear medicine departments if used for research pur-
poses such as to investigate possible links between muco-
ciliary dysfunction and pathophysiology of lung diseases
or pharmacological challenges to the mucociliary appar-
atus [1]. But if used in the work up of patients suspected
of having PCD, the interpretation of tests needs expertise
in addition to a relatively large population of patients (in
concordance with the infrequent nature of the disease).
However, it is yet to be established if these tests/results can
be replicated in less-experienced nuclear medicine facilities
after a proper amount of training.
From the above, we can conclude the following: (1) in
the present study, we found no false negatives. We
therefore believe that PRMC has the ability to reject a
suspected PCD diagnosis with great certainty, when used
in daily clinical work up (in the present study in 2/3 of
referred patients). (2) PRMC has the ability to find can-
didates for further work up. In the present study, 40 %
of patients with an abnormal PRMC test ended up hav-
ing PCD as final clinical diagnosis. This number will of
course depend greatly upon the group of patients being
investigated. (3) PRMC has a high rate of conclusive
results (90 % in the present study). (4) In addition, our
results indicate that there might be a need for reference
material for children.
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